In this study, two standardized and validated prognostic tests—EPclin and uPA/PAI-1- were prospectively compared for the first time with respect to feasibility, risk stratification and influence on adjuvant therapy recommendation in endocrine sensitive, HER2- negative early breast cancer. This evidence concerns the gene SERPINE1 and breast cancer.